← Back to Search

Procedure

RD-X19 for Post-COVID Syndrome (EB-PCC-01 Trial)

N/A

Waitlist Available

Research Sponsored by KNOWBio Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

History of confirmed diagnosis of SARS-CoV-2 infection or COVID-19 per section 9.4

Agrees to maintain current medications without the addition of any new medications for relief of signs and symptoms of PCC during the entire study period, and, if used, to report ALL such medications (including over the counter and home remedies) to the study staff

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 weeks

Awards & highlights

EB-PCC-01 Trial Summary

This trial involves 7 days of treatment, 2 times per day, with weekly televisits and follow up visits up to 5 weeks after.

Who is the study for?

Adults over 22 with long COVID symptoms for at least 2 months post-infection, who haven't taken new meds for these symptoms recently. They must not have other health issues that could explain their symptoms or prevent full participation, and agree to avoid pregnancy.Check my eligibility

What is being tested?

The RD-X19 device is being tested on people with long COVID to see if it helps reduce their symptoms like cough, fatigue, shortness of breath, and brain fog. Participants will use the device twice daily for a week and be monitored through clinic visits and calls.See study design

What are the potential side effects?

Potential side effects are not detailed in the provided information but may include discomfort from using the device or reactions specific to light exposure due to the nature of RD-X19 treatment.

EB-PCC-01 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had a confirmed case of COVID-19.

Select...

I agree not to start any new medications for my condition during the study and will report all medications I take.

Select...

My symptoms have lasted for at least 2 months, continuously or on and off.

Select...

I do not have any uncontrolled chronic or acute diseases causing my symptoms.

Select...

I agree to self-treat twice daily, 6 hours apart, during the treatment.

EB-PCC-01 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Primary Symptom Improvement

Secondary outcome measures

Secondary Symptom Improvement

EB-PCC-01 Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ActiveActive Control1 Intervention

Group II: ShamPlacebo Group1 Intervention

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

KNOWBio Inc.Lead Sponsor

1 Previous Clinical Trials

25 Total Patients Enrolled

NAMSAOTHER

45 Previous Clinical Trials

16,882 Total Patients Enrolled

EmitBio Inc.Lead Sponsor

3 Previous Clinical Trials

573 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current participant headcount for this experiment?

"Affirmative. Clinicaltrials.gov reveals that this experiment, which was first made available on October 30th 2023 is still actively looking for participants to enroll in the study. The scientific team needs at least 60 patients from 2 different sites."

Answered by AI

Are investigators presently searching for participants in this research project?

"Based on the information from clinicaltrials.gov, this research endeavour is actively enrolling participants. Its public profile was created on October 30th 2023 and last updated at that same date."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting

2023. "Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06113679.

All > Survivor Corps